MX2022015335A - Combinacion farmaceutica de un corticosteroide y un antihistaminico para el tratamiento y control del componente inflamatorio de procesos alergicos. - Google Patents

Combinacion farmaceutica de un corticosteroide y un antihistaminico para el tratamiento y control del componente inflamatorio de procesos alergicos.

Info

Publication number
MX2022015335A
MX2022015335A MX2022015335A MX2022015335A MX2022015335A MX 2022015335 A MX2022015335 A MX 2022015335A MX 2022015335 A MX2022015335 A MX 2022015335A MX 2022015335 A MX2022015335 A MX 2022015335A MX 2022015335 A MX2022015335 A MX 2022015335A
Authority
MX
Mexico
Prior art keywords
treatment
antihistamine
corticosteroid
control
pharmaceutical combination
Prior art date
Application number
MX2022015335A
Other languages
English (en)
Inventor
Canudas Jorge Alejandro González
Salazar Claudia Delfina Farfán
León Sixto Serafín Espinoza
Rubio Paola Yazmín Ollervides
Martinez Cecilia Jannette Muñoz
Original Assignee
Laboratorios Silanes S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Silanes S A De C V filed Critical Laboratorios Silanes S A De C V
Publication of MX2022015335A publication Critical patent/MX2022015335A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención combina en una sola unidad de dosificación los fármacos desloratadina y betametasona, lo cual, representa un conjunto de importantes retos tecnológicos debido a las propiedades fisicoquímicas y a la diferencia en dosis para garantizar la obtención de un producto estable para el tratamiento de procesos alérgicos e inflamatorios en un sujeto.
MX2022015335A 2020-12-04 2020-12-04 Combinacion farmaceutica de un corticosteroide y un antihistaminico para el tratamiento y control del componente inflamatorio de procesos alergicos. MX2022015335A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2020/050048 WO2022119428A1 (es) 2020-12-04 2020-12-04 Combinación farmacéutica de un corticosteroide y un antihistamínico para el tratamiento y control del componente inflamatorio de procesos alérgicos

Publications (1)

Publication Number Publication Date
MX2022015335A true MX2022015335A (es) 2023-01-11

Family

ID=81853419

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015335A MX2022015335A (es) 2020-12-04 2020-12-04 Combinacion farmaceutica de un corticosteroide y un antihistaminico para el tratamiento y control del componente inflamatorio de procesos alergicos.

Country Status (8)

Country Link
US (1) US20240024307A1 (es)
EP (1) EP4230211A4 (es)
CA (1) CA3199160A1 (es)
CO (1) CO2023008892A2 (es)
DO (1) DOP2023000093A (es)
MX (1) MX2022015335A (es)
PE (1) PE20252762A1 (es)
WO (1) WO2022119428A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102022006848A2 (pt) * 2022-04-08 2023-10-24 Eurofarma Laboratorios S.A. Uso de prednisolona ou seus sais farmacêuticos ativos em uma composição farmacêutica, composição farmacêutica, seu processo de preparação e seu uso
WO2025263978A1 (ko) * 2024-06-18 2025-12-26 가톨릭대학교 산학협력단 낭성콩팥병 개선 또는 치료용 조성물 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3053865A (en) 1958-03-19 1962-09-11 Merck & Co Inc Novel 16-alkyl and 16-alkylene steroids and processes
JPS61501205A (ja) 1984-02-15 1986-06-19 シェリング・コ−ポレ−ション ８↓−クロル↓−６，１１↓−ジヒドロ↓−１１↓−（４↓−ピペリジリデン）↓−５Ｈ↓−ベンゾ〔５，６〕シクロヘプタ〔１，２−ｂ〕ピリジンおよびその塩、これらの化合物の製造方法、ならびにこれらの化合物を含有する医薬組成物
DE19729516C2 (de) 1997-07-10 1999-04-22 Georg Wiegner Pumpe zum dosierten Austragen von flüssigen, gelartigen oder viskosen Substanzen
WO2000051605A1 (en) 1999-03-01 2000-09-08 Schering Corporation Compositions and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids
EP1696881A2 (en) 2003-12-23 2006-09-06 Sun Pharmaceutical Industries Limited Stable oral composition
WO2006102494A2 (en) * 2005-03-23 2006-09-28 Elan Pharma International Limited Nanoparticulate corticosteroid and antihistamine formulations
US9592241B2 (en) * 2011-12-27 2017-03-14 Cmpd Licensing, Llc Silicone-based composition for skin treatment

Also Published As

Publication number Publication date
EP4230211A4 (en) 2024-09-11
US20240024307A1 (en) 2024-01-25
CA3199160A1 (en) 2022-06-09
CO2023008892A2 (es) 2023-08-18
DOP2023000093A (es) 2023-06-15
WO2022119428A1 (es) 2022-06-09
PE20252762A1 (es) 2025-12-22
EP4230211A1 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
CY1124548T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου
CO2023008892A2 (es) Combinación farmacéutica de un corticosteroide y un antihistamínico para el tratamiento y control del componente inflamatorio de procesos alérgicos
CY1123571T1 (el) Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα
MX2021009037A (es) Composiciones y metodos para el manejo de trastornos.
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CL2018002758A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue.
ES3057783T3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
ES3064032T3 (en) Ophthalmological compositions comprising brimonidine and ketotifen for use in the treatment of allergies
MX2017015838A (es) Composiciones y metodos para tratar pterigion.
CY1110495T1 (el) Χρηση ενος αγωνιστη υποδοχεα nmda για τη θεραπεια εμβοης που προκαλειται απο κοχλιακη διεγερτοτοξικοτητα
CL2018002784A1 (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue.
CO2018003471A2 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue
CL2019002240A1 (es) Dendrímeros terapéuticos.
CL2018002718A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CO2018003369A2 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue
UY37844A (es) Inhibidores de mcl-1 macrocíclicos y métodos de uso
MX2019003397A (es) Metodos para tratar trastornos mitocondriales y metabolicos.
MX2015009269A (es) Composiciones farmaceuticas que comprenden donadores de nitroxilo.
CL2018003502A1 (es) Métodos para tratar la osificación heterotópica.
CY1124893T1 (el) Φαρμακευτικο μeιγμα μαροπιταντης
BR112018074655A2 (pt) formulação injetável de fosnetupitant e método de fabricação de uma formulação
MX2020005006A (es) Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular.
CL2021001635A1 (es) Tratamiento combinado para tumores sólidos con docetaxel y un inhibidor de cyp3a
MX2017012459A (es) Formulacion de complejo farmaceutico que comprende amlodipina, losartan y clortalidona.
BR112018067784A2 (pt) regime de dosagem para o tratamento de exacerbações agudas de condições inflamatórias